Curcumin in Advanced Cervical Cancer

Launched by INSTITUTO NACIONAL DE CANCEROLOGIA, COLUMBIA · Mar 2, 2020

Keywords

ClinConnect Summary

A placebo-controlled phase II clinical trial will be developed in patients with advanced cervical cancer who have an indication for radiotherapy. Those who accept to participate will receive the standard treatment with established chemo-radiation and will be randomized in two arms, the experimental will receive 500mg of the commercial presentation (curcugreen) c / 6h VO x 16 weeks and the control arm will receive placebo. The operative hypotheses are: the addition of curcumin to the treatment improves the cumulative probability of 3-year overall survival by 20% and improves the treatment re...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women aged 18 years or older
• • Voluntary acceptance of participation and signing of informed consent
• • Radiotherapy indication
• • Histological confirmation of squamous cervical cancer or histologically confirmed adenocarcinoma
• • Stage IIB - VAT
• • Chemo-radiation indication with Cisplatin, Cisplatin/fluorouracil, Carboplatin (if cisplatin intolerant)
• • ECOG equal to or less than 1 and a Karnofsky index equal to or greater than 70%.
• Exclusion Criteria:
• • Being pregnant or breastfeeding
• • Presence of second concomitant neoplasia
• • Any previous surgical, radiotherapy or chemotherapy treatment.
• • Diagnosis of invasive recurrent carcinoma of the cervix
• • Receive anticoagulant therapy
• • Receive immunosuppression therapy
• • Presence of coagulation disorders, such as platelet count less than 100,000 at the time of the joint evaluation, absolute neutrophil count less than 1,500 / ml
• • Presence of signs of systemic infection
• • Renal failure, creatinine clearance less than 45 ml/min confirmed with glomerular filtration less than 45 ml / min; evidence of unilateral renal exclusion
• • Patients with uncontrolled metabolic disease